AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23934002 — intervention group
Group type: EXPERIMENTAL
Intervention: Change Questionnaire (12-item instrument assessing motivation to change)
Number of subjects: 213
Study 23934002 — intervention group
Group type: EXPERIMENTAL
Intervention: Change Questionnaire subscale 'Ability to change'
Number of subjects: 213
Study 23934002 — intervention group
Group type: EXPERIMENTAL
Intervention: Change Questionnaire overall score
Number of subjects: 213
Study 23934002 — intervention group
Group type: EXPERIMENTAL
Intervention: Change Questionnaire subscale 'Other change language dimensions'
Number of subjects: 213
Study 21310080 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice flavonoid oil (LFO)
Number of subjects: 22
Study 21310080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20021675 — intervention group
Group type: EXPERIMENTAL
Intervention: dry‐needling, advice and exercise
Number of subjects: 120
Study 20021675 — intervention group
Group type: COMPARATOR
Intervention: sham dry‐needling, advice and exercise
Number of subjects: 120
Study 16739844 — intervention group
Group type: EXPERIMENTAL
Intervention: Governor Vessel Daoqi needling method combined with antidepressants
Number of subjects: 45
Study 16739844 — intervention group
Group type: COMPARATOR
Intervention: Simple antidepressants
Number of subjects: 45
Study 15193938 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual paired comparison task (VPC)
Number of subjects: 1
Study 15193938 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed matching to sample (DMS) task
Number of subjects: 1
Study 10943230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 116
Study 10943230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 9051333 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 0
Study 9051333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 100 mg
Number of subjects: 0
Study 9051333 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for injection
Number of subjects: 0
Study 9051333 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral and subcutaneous sumatriptan
Number of subjects: 0
Study 8377981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g single oral dose) for women and their partners
Number of subjects: 250
Study 8377981 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole (2 g single oral dose) for women
Number of subjects: 250
Study 8377981 — intervention group
Group type: COMPARATOR
Intervention: Placebo for male partners
Number of subjects: 250
Study 3803198 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tilidine
Number of subjects: 0
Study 3803198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular tilidine
Number of subjects: 0
Study 3803198 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine, codeine, d-propoxyphene
Number of subjects: 0
Study 3803198 — intervention group
Group type: COMPARATOR
Intervention: Parenteral morphine
Number of subjects: 0
Study 3384584 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 200 mg dl‐alpha‐tocopheryl acetate
Number of subjects: 6
Study 3384584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31541495 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 infection with borderline/low-grade cytology
Number of subjects: 379
Study 31541495 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 infection with normal cytology
Number of subjects: 379
Study 31541495 — intervention group
Group type: EXPERIMENTAL
Intervention: Other HPV types with borderline/low-grade cytology
Number of subjects: 379
Study 31541495 — intervention group
Group type: EXPERIMENTAL
Intervention: Other HPV types with normal cytology
Number of subjects: 379
Study 31541495 — intervention group
Group type: EXPERIMENTAL
Intervention: New HPV infection in women with normal to low-grade cytology
Number of subjects: 379
Study 28303587 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX + 250 mg of MTZ for 14 days
Number of subjects: 109
Study 28303587 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX + 400 mg of MTZ for 14 days
Number of subjects: 109
Study 28303587 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 or 400 mg of MTZ for 7 days
Number of subjects: 109
Study 28303587 — intervention group
Group type: COMPARATOR
Intervention: SRP-only
Number of subjects: 109
Study 26964159 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer and winter acupuncture group
Number of subjects: 240
Study 26964159 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-summer and winter acupuncture group
Number of subjects: 240
Study 26964159 — intervention group
Group type: COMPARATOR
Intervention: Western medication group (cetirizine)
Number of subjects: 240
Study 23727881 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing neutral faces in a social task
Number of subjects: 21
Study 23727881 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing emotional expressions in a social task
Number of subjects: 21
Study 23727881 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing neutral faces
Number of subjects: 21
Study 23727881 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing emotional faces
Number of subjects: 21
Study 23727881 — intervention group
Group type: EXPERIMENTAL
Intervention: Social task
Number of subjects: 21
Study 23727881 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender task
Number of subjects: 21
Study 21284065 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioral therapy
Number of subjects: 31
Study 21284065 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 31
Study 19482866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (5 mg/day for seven 5-day courses)
Number of subjects: 84
Study 19482866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 19482866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 84
Study 16522140 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller object with static noise pattern
Number of subjects: 0
Study 16522140 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger object with dynamic noise
Number of subjects: 0
Study 12740678 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac 2 x 100 mg daily
Number of subjects: 227
Study 12740678 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac resinate 2 x 75 mg daily
Number of subjects: 227
Study 12740678 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Number of subjects: 227
Study 12740678 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac resinate
Number of subjects: 227
Study 10699617 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged combined androgen blockade (CAB) therapy (120 days or more)
Number of subjects: 813
Study 10699617 — intervention group
Group type: COMPARATOR
Intervention: Short-term combined androgen blockade (CAB) therapy (less than 120 days)
Number of subjects: 813
Study 10699617 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged CAB therapy (120 days or more) in patients who lived at least 2 years
Number of subjects: 813
Study 9328500 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate 1332 mg/day
Number of subjects: 0
Study 9328500 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate 1998 mg/day
Number of subjects: 0
Study 9328500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8229496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG), 0.5 ml/kg, administered intramuscularly at entry and 30 days later.
Number of subjects: 76
Study 8229496 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo, administered intramuscularly at entry and 30 days later.
Number of subjects: 76
Study 3096180 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal perfusion of hydrochloric acid (HCl)
Number of subjects: 12
Study 3096180 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NaCl)
Number of subjects: 12
Study 3096180 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal perfusion of hydrochloric acid (HCl) in subjects with GER
Number of subjects: 12
Study 29313180 — intervention group
Group type: COMPARATOR
Intervention: Pasireotide subcutaneous treatment (300–600 μg s.c. twice-daily)
Number of subjects: 7
Study 29313180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release (LAR) treatment (40–60 mg monthly)
Number of subjects: 7
Study 29313180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide treatment overall
Number of subjects: 7
Study 29313180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide treatment
Number of subjects: 7
Study 26708314 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg aspirin daily for up to 24 weeks
Number of subjects: 0
Study 26708314 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for up to 24 weeks
Number of subjects: 0
Study 25906770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 60
Study 25906770 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 60
Study 23676420 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy after 4 months of chemotherapy
Number of subjects: 79
Study 23676420 — intervention group
Group type: COMPARATOR
Intervention: Continuation of chemotherapy
Number of subjects: 79
Study 19948082 — intervention group
Group type: EXPERIMENTAL
Intervention: Being mindset
Number of subjects: 0
Study 19948082 — intervention group
Group type: EXPERIMENTAL
Intervention: Becoming mindset
Number of subjects: 0
Study 19040013 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK intravenous infusion for 24 hours plus routine treatment (3739 patients)
Number of subjects: 7510
Study 19040013 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving routine treatment alone (3771 patients)
Number of subjects: 7510
Study 16373887 — intervention group
Group type: EXPERIMENTAL
Intervention: Active titration with laboratory A1C testing
Number of subjects: 7893
Study 16373887 — intervention group
Group type: EXPERIMENTAL
Intervention: Active titration with POC A1C testing
Number of subjects: 7893
Study 16373887 — intervention group
Group type: COMPARATOR
Intervention: Usual titration with laboratory A1C testing
Number of subjects: 7893
Study 16373887 — intervention group
Group type: COMPARATOR
Intervention: Usual titration with POC A1C testing
Number of subjects: 7893
Study 12602372 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin + cold red laser therapy
Number of subjects: 120
Study 12602372 — intervention group
Group type: COMPARATOR
Intervention: Placebo + cold red laser therapy
Number of subjects: 120
Study 9929752 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Fr diagnostic catheters
Number of subjects: 100
Study 9929752 — intervention group
Group type: COMPARATOR
Intervention: 5Fr diagnostic catheters
Number of subjects: 100
Study 8672944 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings with 12 mmHg pressure
Number of subjects: 80
Study 8672944 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings with 20 mmHg pressure
Number of subjects: 80
Study 8672944 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings with 30 mmHg pressure
Number of subjects: 80
Study 8672944 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 80
Study 2271125 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS‐90 (60 mmol/L sodium, 90 mmol/L glucose, osmolality 311 mOsm/kg)
Number of subjects: 186
Study 2271125 — intervention group
Group type: COMPARATOR
Intervention: ORS‐60 (60 mmol/L sodium, 90 mmol/L glucose, osmolality 240 mOsm/kg)
Number of subjects: 186
Study 7282695 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up telephone call (Group 2)
Number of subjects: 82
Study 7282695 — intervention group
Group type: EXPERIMENTAL
Intervention: Written and oral consultation (Group 3)
Number of subjects: 82
Study 7282695 — intervention group
Group type: EXPERIMENTAL
Intervention: Written and oral consultation plus call-back (Group 4)
Number of subjects: 82
Study 7282695 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 7282695 — intervention group
Group type: EXPERIMENTAL
Intervention: Written and oral consultation
Number of subjects: 82
Study 7282695 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up telephone call
Number of subjects: 82
Study 29992904 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 0
Study 29992904 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 0
Study 26562686 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic future thinking (EFT)
Number of subjects: 29
Study 26562686 — intervention group
Group type: COMPARATOR
Intervention: Control episodic recent thinking (ERT)
Number of subjects: 29
Study 24445245 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole 1-15 mg/day
Number of subjects: 22
Study 24445245 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole 10-20 mg/day
Number of subjects: 22
Study 24445245 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole 15-28.1 mg/day
Number of subjects: 22
Study 24445245 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole 20-30 mg/day
Number of subjects: 22
Study 24445245 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole 10 mg/day
Number of subjects: 22
Study 24445245 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole <10 mg/day
Number of subjects: 22
Study 22221492 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon
Number of subjects: 126
Study 22221492 — intervention group
Group type: EXPERIMENTAL
Intervention: Herring
Number of subjects: 126
Study 22221492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pompano
Number of subjects: 126
Study 22221492 — intervention group
Group type: COMPARATOR
Intervention: Control (meat mix)
Number of subjects: 126
Study 20684264 — intervention group
Group type: EXPERIMENTAL
Intervention: New compound codonopsis tablets
Number of subjects: 45
Study 20684264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 17885563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine 10 mg once daily for 24 weeks
Number of subjects: 50
Study 17885563 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily for 24 weeks
Number of subjects: 50
Study 16036441 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-by-step administration of the ROCF
Number of subjects: 132
Study 16036441 — intervention group
Group type: COMPARATOR
Intervention: Standard administration of the ROCF
Number of subjects: 132
Study 12142111 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial pacing with leads sited at the high right atrium (HRA) and distal coronary sinus (DCS)
Number of subjects: 19
Study 12142111 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial (RA) pacing
Number of subjects: 19
Study 12142111 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus (CS) pacing
Number of subjects: 19
Study 12142111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential pacing
Number of subjects: 19
Study 12142111 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous pacing
Number of subjects: 19
Study 12142111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19
Study 10186224 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer (repeated screening every third year for four rounds)
Number of subjects: 9169
Study 10186224 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 9169
Study 10186224 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 9169
Study 7746765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive educational interventions
Number of subjects: 36
Study 7746765 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 2687558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmorubicin
Number of subjects: 30
Study 2687558 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 30
Study 29614982 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic focus on subtle changes during the check-in phase lasting from 7 to 20 minutes
Number of subjects: 0
Study 29614982 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art (SOTA) check-in phase lasting several minutes focused on session goals
Number of subjects: 0
Study 28150955 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient care for 21 days plus 6 months of continuing care
Number of subjects: 176
Study 28150955 — intervention group
Group type: COMPARATOR
Intervention: Outpatient care for 21 days plus 6 months of continuing care
Number of subjects: 176
Study 28150955 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient care
Number of subjects: 176
Study 26652866 — intervention group
Group type: EXPERIMENTAL
Intervention: tools + basic training (Arm I)
Number of subjects: 0
Study 26652866 — intervention group
Group type: EXPERIMENTAL
Intervention: tools + enhanced training + facilitation (Arm II)
Number of subjects: 0
Study 26652866 — intervention group
Group type: COMPARATOR
Intervention: Propensity score-matched control group of clinics
Number of subjects: 0
Study 23522245 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management of blood pressure (BP)
Number of subjects: 540
Study 23522245 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 540
Study 22083986 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AAG)
Number of subjects: 24
Study 22083986 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (NCG)
Number of subjects: 24
Study 19808133 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN monohydrate 10 mg once daily for 12 weeks
Number of subjects: 438
Study 19808133 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 438
Study 16460246 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival instrumentation using PVP-I (10%) as the cooling liquid
Number of subjects: 44
Study 16460246 — intervention group
Group type: COMPARATOR
Intervention: Identical treatment using distilled water as the cooling liquid (control)
Number of subjects: 44
Study 16460246 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 15255451 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin-trace element supplement
Number of subjects: 44
Study 15255451 — intervention group
Group type: COMPARATOR
Intervention: Placebo containing calcium
Number of subjects: 44
Study 11261333 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized uni‐ or biventricular pacing therapy
Number of subjects: 50
Study 11261333 — intervention group
Group type: COMPARATOR
Intervention: Conventional right ventricular stimulation
Number of subjects: 50
Study 9278200 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 750 mg, three times a day for 5 days
Number of subjects: 12
Study 9278200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7865647 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily
Number of subjects: 81
Study 7865647 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg weekend
Number of subjects: 81
Study 2577500 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F 94482 (BMY-25368) 400 mg
Number of subjects: 11
Study 2577500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 778649 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1.5 to 6.0 mg/kg every 4 h)
Number of subjects: 66
Study 778649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no furosemide)
Number of subjects: 66
Study 778649 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 66
Study 31535302 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental follow-up schedule group (ESG, n=87)
Number of subjects: 180
Study 31535302 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up schedule group (CSG, n=93)
Number of subjects: 180
Study 31535302 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 180
Study 31535302 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental follow-up schedule group (ESG)
Number of subjects: 180
Study 31375523 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 45
Study 31375523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 45
Study 31375523 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic greater curvature plication
Number of subjects: 45
Study 31375523 — intervention group
Group type: COMPARATOR
Intervention: RYGB or SG (in validation cohort)
Number of subjects: 45
Study 31375523 — intervention group
Group type: COMPARATOR
Intervention: RYGB or SG (in derivation cohort)
Number of subjects: 45
Study 28585840 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 44
Study 28585840 — intervention group
Group type: COMPARATOR
Intervention: Control (no octreotide)
Number of subjects: 44
Study 24859784 — intervention group
Group type: EXPERIMENTAL
Intervention: 1970s baseline measurements
Number of subjects: 1454
Study 24859784 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000s follow-up measurements
Number of subjects: 1454
Study 24859784 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared genetic contribution
Number of subjects: 1454
Study 24859784 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared environmental contributions
Number of subjects: 1454
Study 22554102 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.13% hyaluronic acid (HA) solution
Number of subjects: 196
Study 22554102 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 196
Study 20981007 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 369
Study 20981007 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB2 promoter polymorphisms
Number of subjects: 369
Study 20981007 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB2 promoter haplotype
Number of subjects: 369